Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis
Nutrients · 10.01.2023 · 15 (2) · 350
DOI: 10.3390/nu15020350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 10.01.2023. Verfasst von Takayuki Inoue und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, …. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Abstract (Originalsprache)
The molecular pathogenesis of nonalcoholic steatohepatitis (NASH) includes a complex interaction of metabolic stress and inflammatory stimuli. Considering the therapeutic goals of NASH, it is important to determine whether the treatment can prevent the progression from NASH to hepatocellular carcinoma. Taxifolin, also known as dihydroquercetin, is a natural bioactive flavonoid with antioxidant and anti-inflammatory properties commonly found in various foods and health supplement products. In this study, we demonstrated that Taxifolin treatment markedly prevented the development of hepatic steatosis, chronic inflammation, and liver fibrosis in a murine model of NASH. Its mechanisms include a direct action on hepatocytes to inhibit lipid accumulation. Taxifolin also increased brown adipose tissue activity and suppressed body weight gain through at least two distinct pathways: direct action on brown adipocytes and indirect action via fibroblast growth factor 21 production in the liver. Notably, the Taxifolin treatment after NASH development could effectively prevent the development of liver tumors. Collectively, this study provides evidence that Taxifolin shows pleiotropic effects for the treatment of the NASH continuum. Our data also provide insight into the novel mechanisms of action of Taxifolin, which has been widely used as a health supplement with high safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan.
- Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan.
- Department of Immunometabolism, Nagoya University Graduate School of Medicine, Nagoya 464-8601, Japan.
- Department of Laboratory Molecular Genetics of Hematology, Graduate School of Medical and Dental University, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.
- Institute of Nano-Life-Systems, Institutes of Innovation for Future Society, Nagoya University, Nagoya 464-8601, Japan.
- Department of Physical Therapy, Health Science University, Yamanashi 401-0380, Japan.
ORCID-Profile: Hisashi Kato, Masashi Tanaka, Yukihiro Shiraki, Satoshi Saito, Masafumi Ihara, Kumiko Saeki, Atsushi Enomoto, Takayoshi Suganami, Noriko Satoh-Asahara
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science, and Technology of Japan
- Research Program on Hepatitis
- Research Program on Rare and Intractable Diseases
- SEI Group CSR Foundation
- ONO Medical Research Foundation
- KOSE Cosmetology Research Foundation
Zitieren
APA
Inoue, T., Fu, B., Nishio, M., Tanaka, M., Kato, H., Tanaka, M., Itoh, M., Yamakage, H., Ochi, K., Ito, A., Shiraki, Y., Saito, S., Ihara, M., Nishimura, H., Kawamoto, A., Inoue, S., Saeki, K., Enomoto, A., Suganami, T., & Satoh-Asahara, N. (2023). Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis. Nutrients, 15(2), 350. https://doi.org/10.3390/nu15020350
Vancouver
Inoue T, Fu B, Nishio M, Tanaka M, Kato H, Tanaka M, et al. Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis. Nutrients. 2023;15(2):350. doi:10.3390/nu15020350
BibTeX
@article{Inoue2023,
author = {Inoue, Takayuki and Fu, Bin and Nishio, Miwako and Tanaka, Miyako and Kato, Hisashi and Tanaka, Masashi and Itoh, Michiko and Yamakage, Hajime and Ochi, Kozue and Ito, Ayaka and Shiraki, Yukihiro and Saito, Satoshi and Ihara, Masafumi and Nishimura, Hideo and Kawamoto, Atsuhiko and Inoue, Shian and Saeki, Kumiko and Enomoto, Atsushi and Suganami, Takayoshi and Satoh-Asahara, Noriko},
title = {Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {2},
pages = {350},
doi = {10.3390/nu15020350}
}
EUVIMED